CPHI & PMEC China 2025 Positions China as Global Pharma Innovator and Regulatory Collaborator
Cementing its place as Asia’s largest and most influential pharmaceutical exhibition, CPHI & PMEC China 2025 welcomed over 90,000 industry professionals, 3,500+ exhibitors, and hosted 100+ thought leadership sessions from June 23 to 26 at the Shanghai New International Expo Center. With a clear focus on innovation, international collaboration, and regulatory alignment, the event underscored China’s dual role as a manufacturing powerhouse and an emerging global hub for pharma innovation.
Theme: “Turning Local Connections into Endless Opportunity”
This year’s theme spotlighted China’s growing importance in the global pharmaceutical supply chain. From APIs and biologics to excipients and advanced drug delivery systems, the exhibition offered a comprehensive look at the future of pharma. The event also became a high-impact platform for deal-making, cross-border collaboration, and regulatory dialogue.
Strategic Forum Opens the Dialogue:
Kicking off the event, a high-level policy and strategy forum was held at Purple Mountain Hotel on June 23. Attended by regulators, government officials, and industry leaders, the session focused on regulatory harmonisation, international trade, and pharmaceutical diplomacy.
Key Speakers & Highlights:
- Zhou Hui, President, CCCMHPIE
“China must lead by balancing quality, innovation, and compliance—a three-pronged strategy to strengthen global competitiveness.”
- Zhang Wei, Executive President, China Society for Drug Regulation
Emphasised urgent alignment with global frameworks such as ICH and WHO standards to facilitate smoother global market access.
- Meng Xiaofeng, Vice President, Haisco Biopharma
“GMP is the entry ticket—not the journey’s end. True competitiveness lies in scale-up, innovation, and patient-focused development.”
Key Discussions and Takeaways:
Global Trade Forecast & Export Growth
China’s Ministry of Commerce projected double-digit export growth, especially in biologics, identifying Asia-Pacific and Africa as high-potential regions.
China–ASEAN Drug Procurement Collaboration
Ongoing drug procurement frameworks with ASEAN countries were spotlighted, promoting shared regulatory pathways and bulk buying mechanisms for faster access to essential medicines.
US & EU Market Access
Experts shared insights on:
- Aligning with regulatory science standards
- Investing in real-world evidence (RWE)
- Strategic overseas manufacturing for compliance with FDA and EMA norms
Belt & Road Initiative: Pharma as Health Diplomacy
BRI was redefined as a biopharma growth engine, offering:
- Joint ventures
- Tech transfer programs
- Cross-border clinical trials across Africa, Central Asia, and Eastern Europe
CPHI & PMEC China 2025: A Global Pharma Nexus
With exhibitors ranging from raw material providers to biotech startups and digital health pioneers, CPHI & PMEC China has transformed into a global convergence point for pharmaceutical progress.
The 2025 edition reinforced China’s ambition not just as a cost-efficient producer, but as a policy-driven, innovation-focused, and globally engaged pharma leader.